Genetic Technologies (ASX: GTG) has already surpassed gross revenues generated by its non-coding DNA technology licensing program in the 2012 financial year in just the first five months of the 2013 financial year.
Importantly, the non-dilutive funding has added substantially to the company’s cash reserves as at 30 November 2012, which exceeded $7.5 million.
The intellectual property out-licensing program provides a contracted annuity stream of $5.5 million through to 2015.
Over 65 licences have been awarded, generating around $70 million in revenue so far, with $13.5 million of that secured from nine contracts in 2011 alone – marking a record licensing year for Genetic.
The company has several patent families protecting the use of its non-coding DNA for genetic analysis.
Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX “Small and Mid-cap” stocks with distribution in Australia, UK, North America and Hong Kong / China.